-
June 8, 2020
New Treatments for Ovarian Cancer in 2020
Smruti Vidwans, PhDWomen with ovarian cancer once relied solely on chemotherapy to treat their disease. However, in recent years, treatment options have expanded, and new options are also on the horizon. Read… Read more »
-
September 1, 2020
Ovarian Cancer—An OverviewBookmark
George Lundberg, MDCurated by Editor in Chief George Lundberg, MD, who notes:
Medscape has published this excellent, authoritative, comprehensive overview of ovarian cancer, which includes information on diagnosis and treatment. (Written with a physician audience in mind.)
.
-
August 7, 2020
Clinical Challenges: Platinum-Resistant Ovarian CancerBookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark
George Lundberg, MDArticle from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.
Go to full article published by GenomeWeb.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian CancerBookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 2, 2020
FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian CancerBookmark
George Lundberg, MDPress release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.
Go to full article published by the FDA.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Show More
E. David Crawford, MD
Cancer Commons Advisor
-
February 7, 2017
Testing for Tumor Mutations: Liquid Biopsy Versus Traditional Biopsy
Emma Shtivelman, PhDUpdate as of August 27, 2020: A lot has changed in the three-and-a-half years since this blog post was written. Liquid biopsies are by now widely recognized and used as… Read more »
-
February 11, 2020
Carcinoma of Unknown Primary Case Reviewed in Tumor Board SessionBookmark
George Lundberg, MDArticle from CAP Today curated by Editor in Chief George Lundberg, MD, who notes:
Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.
Go to full article published by CAP Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
November 12, 2019
FDA Approves Test for Late-line HRD+ Ovarian CancerBookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
A new diagnostic test and new therapeutic drugs have received approval from the U.S. Food and Drug Administration (FDA) for certain advanced ovarian cancers, which are always difficult to treat.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Show More
Latest Clinical Trial Results in Ovarian Cancer
Some of the most promising new treatments for advanced ovarian cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.
-
August 7, 2020
Final Results from KEYNOTE-100 Show Promise for Pembrolizumab MonotherapyBookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
Treatment with pembrolizumab (brand name Keytruda) on its own shows modest responses in patients with recurrent ovarian cancer.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology StudyBookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 6, 2020
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerBookmark
George Lundberg, MDResearch paper from The New England Journal of Medicine curated by Editor in Chief George Lundberg, MD, who notes:
These clinical trials results suggest that the drug niraparib is superior to platinum-based chemotherapy for people with newly diagnosed advanced ovarian cancer.
Go to full paper published in The New England Journal of Medicine.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
PARP Inhibitors Center Stage for Ovarian CancerBookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialBookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Show More
Navigating Treatment
The world of advanced cancer treatment can be complex and confusing. Get oriented with tips on what to ask your doctor, second opinions, how to enroll in a clinical trial, and more.
-
August 18, 2020
Tumor Boards—What Are They and How Can They Help You?
One of the most powerful tools in cancer treatment today is the tumor board—a group of cancer experts who delve into individual cancer patients’ cases to help them explore their… Read more »
-
June 30, 2020
Helping Cancer Patients Access their Own Health Data
With:For many cancer patients, the ability to access one’s own medical records can aid their treatment decisions, or allow them to donate their personal data for research that could help… Read more »
-
September 6, 2019
What Questions Should I Ask My Doctor?
Sarah StanleyWhen faced with an advanced cancer diagnosis, it can be difficult to know what questions to ask. At Cancer Commons, we help patients and caregivers navigate a vast sea of… Read more »
-
May 21, 2019
Can You Improve Your Response to Certain Immunotherapy Drugs?
Emma Shtivelman, PhDCancer treatments that use a strategy called immune checkpoint blockade (ICB) have entered clinical practice in a big way, with six drugs now approved by the U.S. Food and Drug… Read more »
-
March 19, 2019
At Diagnosis, What Do Cancer Patients Want?
With:A Q&A with Laura Benson, RN, MS, ANP, president of Conversations in Care, LLC; LauraBensonRN@Gmail.com Q: In our digital communication world of 2019, some patients may receive the initial message that… Read more »
-
August 22, 2018
ASCO and Friends Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial ParticipationBookmark
Emma Shtivelman, PhDExcerpt:
“ASCO and Friends of Cancer Research (Friends) have submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.”
Go to full article published by The ASCO Post on Aug 9, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Show More
Gavin Gordon, PhD
Molecular Pathologist
Living With Cancer
Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.
-
October 14, 2019
Pediatric Palliative Care: A Specialty Comes of Age
For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is… Read more »
-
February 11, 2020
‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 7, 2019
Emphasizing Oncogeriatrics
With:A Q&A with Nicolò Matteo Luca Battisti, MD, Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, United Kingdom, and Chair of the Young Interest Group of the International… Read more »
-
December 3, 2018
Best Uses of Physical Medicine and Rehabilitation in Patients with Cancer
With:A Q&A with Val Jones, MD, Medical Director of Admissions, Saint Luke’s Rehabilitation Institute, Spokane, WA Originally published February 1, 2017 Q: Your principal practice in Spokane, Washington is physical… Read more »
-
September 14, 2018
Huge Progress in Palliative Care
With:A Q&A with Diane E. Meier, MD, FACP, Director, Center to Advance Palliative Care; Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai; New York, NY;… Read more »
-
July 23, 2018
Cancer Pain and the Opioid Epidemic
George Lundberg, MDA Q&A with Kevin Sevarino, MD, PhD, President-elect of the American Academy of Addiction Psychiatry and Consulting Psychiatrist at Gaylord Hospital in Wallingford, CT Q: Opioid abuse, addiction, and overdose… Read more »
Show More
-
Molecular Testing Guides Treatment for Claudius’s Lung Cancer
Sarah Stanley Science Writer at Cancer Commons
-
How to Advocate for Yourself: Advice from an Empowered Lymphoma Patient
Brad Power Lymphoma patient and Founder of Reengineering Cancer Treatment
-
Grace Faces Anal Cancer with Strength, Support, and Song
Sarah Stanley Science Writer at Cancer Commons
-
Pushing for the Best Possible Treatment for My Stage 4 Breast Cancer
Karen Peterson Advanced breast cancer patient
-
Carla Takes Charge of Her Own Lung Cancer Treatment
Carla A Cancer Commons lung cancer patient
The Big Picture
Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.
-
September 9, 2020
Is Cancer the Best Way to Die?
With:In 2014, the prestigious medical research journal The BMJ published a controversial piece called “Dying of cancer is the best death.” Here, our Curious Dr. George asks the author of that… Read more »
-
August 21, 2020
The Power of Precision Medicine is Exemplified by Tempus
With:Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.
-
June 29, 2020
Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark
Lola Rahib, PhDArticle from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.
In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.
Go to full article published by ASCO Daily News.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
What Have I Learned in More Than Half a Century in Cancer Medicine?Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
“Patients with cancer need to be embraced with love and compassion. They need caring beyond medicine.”Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
April 27, 2020
The Challenges of Using Artificial Intelligence to Improve Cancer Treatment
With: Razelle Kurzrock, MDJeff Shrager, PhDIn a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile.… Read more »
-
March 2, 2020
Using Artificial Intelligence to Match Combination Targeted Therapies in Oncology
With: Razelle Kurzrock, MDA Q&A with Razelle Kurzrock, MD, Director of the Center for Personalized Cancer Therapy and the Rare Tumor Clinic at U.C. San Diego, and Co-Founder and Board Member of CureMatch,… Read more »
Show More
Cancer and Covid-19
The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.
-
June 10, 2020
How I Cope with the Tsunami of Cancer and COVID-19 Info
With: Kevin Knopf, MD, MPHOncologists worldwide face the challenge of staying on top of the latest treatments, research findings, and other information that could help them treat their patients more effectively. Now, they must… Read more »
-
August 7, 2020
Clinical Trials Gone VirtualBookmark
George Lundberg, MDArticle from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes:
During the COVID-19 pandemic, some clinical trials have gone virtual.
Go to full article published by GenomeWeb.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 20, 2020
How the Coronavirus Pandemic Impacts Cancer Care: Our Survey Results
With: Lola Rahib, PhDThe ongoing COVID-19 pandemic presents unprecedented challenges to cancer patients. Many have experienced changes to their care, and some face increased risk of infection or worse prognosis if they are… Read more »
-
April 14, 2020
What Cancer Patients and Caregivers Need to Know About the Coronavirus Disease
In light of the ongoing coronavirus disease (COVID-19) pandemic, cancer patients may be wondering how their medical situation affects their vulnerability to infection and other ways the pandemic will affect… Read more »
-
April 3, 2020
How to Beat COVID-19 with Real-Time, Real-World Data
With: Mark Shapiro, PhDAs the COVID-19 pandemic continues, researchers around the world are working quickly to develop strategies to treat and prevent this disease. In partnership with the company xCures, Cancer Commons is… Read more »
-
March 17, 2020
These Underlying Conditions Make Coronavirus More Severe, and They’re Surprisingly CommonBookmark
George Lundberg, MDExcerpt from a National Geographic article:
“For now, the sole intervention for vulnerable cancer patients is social distancing and enhanced hygiene practices for their family and health care workers.”
Go to full article published by National Geographic.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Show More
